Comparisons in fluctuation of muscle strength and function in patients with immune-mediated neuropathy treated with intravenous versus subcutaneous immunoglobulin

Ingelise Christiansen; Lars H Markvardsen; Johannes Jakobsen

doi:10.1002/mus.25967

Comparisons in fluctuation of muscle strength and function in patients with immune-mediated neuropathy treated with intravenous versus subcutaneous immunoglobulin

Ingelise Christiansen, Lars H Markvardsen, Johannes Jakobsen

Research output: Contribution to journal › Journal article › Research › peer-review

13 Citations (Scopus)

Abstract

INTRODUCTION: Variations in muscle strength and function have not been studied in patients with chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy whose treatment regimen has been changed from intravenous to subcutaneous immunoglobulin (IVIg to SCIg).

METHODS: In a prospective, open-label study, patients were changed from monthly IVIg to weekly SCIg. The primary endpoint was variation in isokinetic muscle strength (cIKS). Secondary endpoints were variations in Medical Research Council (MRC) score, grip strength (GS), 9-hole-peg test (9-HPT), and 40-meter-walk test (40-MWT).

RESULTS: The coefficient of variance of cIKS during the IVIg and SCIg treatment periods was unchanged (mean ± SD: 6.97 ± 4.83% vs. 5.50 ± 3.13%, P = 0.21). The variations in the 9-HPT and 40-MWT were significantly lower in the SCIg group (P = 0.01 and P = 0.005, respectively).

CONCLUSION: When therapy was changed from IVIg to SCIg, fluctuation of muscle strength was unchanged, but performance fluctuations were diminished. Muscle Nerve, 2017.

Original language	English
Journal	Muscle & Nerve
Volume	57
Issue number	4
Pages (from-to)	610-614
Number of pages	5
ISSN	0148-639X
DOIs	https://doi.org/10.1002/mus.25967
Publication status	Published - 2018
Externally published	Yes

Keywords

chronic inflammatory demyelinating polyneuropathy
intravenous immunoglobulin
multifocal motor neuropathy
subcutaneous immunoglobulin

Access to Document

10.1002/mus.25967

AUB Link

Search for the material in Aalborg University Library's search engine

Cite this

@article{52a6a6e538904b1a8d3a2d6098323771,

title = "Comparisons in fluctuation of muscle strength and function in patients with immune-mediated neuropathy treated with intravenous versus subcutaneous immunoglobulin",

abstract = "INTRODUCTION: Variations in muscle strength and function have not been studied in patients with chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy whose treatment regimen has been changed from intravenous to subcutaneous immunoglobulin (IVIg to SCIg).METHODS: In a prospective, open-label study, patients were changed from monthly IVIg to weekly SCIg. The primary endpoint was variation in isokinetic muscle strength (cIKS). Secondary endpoints were variations in Medical Research Council (MRC) score, grip strength (GS), 9-hole-peg test (9-HPT), and 40-meter-walk test (40-MWT).RESULTS: The coefficient of variance of cIKS during the IVIg and SCIg treatment periods was unchanged (mean ± SD: 6.97 ± 4.83% vs. 5.50 ± 3.13%, P = 0.21). The variations in the 9-HPT and 40-MWT were significantly lower in the SCIg group (P = 0.01 and P = 0.005, respectively).CONCLUSION: When therapy was changed from IVIg to SCIg, fluctuation of muscle strength was unchanged, but performance fluctuations were diminished. Muscle Nerve, 2017.",

keywords = "chronic inflammatory demyelinating polyneuropathy, intravenous immunoglobulin, multifocal motor neuropathy, subcutaneous immunoglobulin",

author = "Ingelise Christiansen and Markvardsen, {Lars H} and Johannes Jakobsen",

note = "{\textcopyright} 2017 Wiley Periodicals, Inc.",

year = "2018",

doi = "10.1002/mus.25967",

language = "English",

volume = "57",

pages = "610--614",

journal = "Muscle & Nerve",

issn = "0148-639X",

publisher = "Wiley",

number = "4",

}

Comparisons in fluctuation of muscle strength and function in patients with immune-mediated neuropathy treated with intravenous versus subcutaneous immunoglobulin. / Christiansen, Ingelise; Markvardsen, Lars H; Jakobsen, Johannes.
In: Muscle & Nerve, Vol. 57, No. 4, 2018, p. 610-614.

Research output: Contribution to journal › Journal article › Research › peer-review

TY - JOUR

T1 - Comparisons in fluctuation of muscle strength and function in patients with immune-mediated neuropathy treated with intravenous versus subcutaneous immunoglobulin

AU - Christiansen, Ingelise

AU - Markvardsen, Lars H

AU - Jakobsen, Johannes

PY - 2018

Y1 - 2018

N2 - INTRODUCTION: Variations in muscle strength and function have not been studied in patients with chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy whose treatment regimen has been changed from intravenous to subcutaneous immunoglobulin (IVIg to SCIg).METHODS: In a prospective, open-label study, patients were changed from monthly IVIg to weekly SCIg. The primary endpoint was variation in isokinetic muscle strength (cIKS). Secondary endpoints were variations in Medical Research Council (MRC) score, grip strength (GS), 9-hole-peg test (9-HPT), and 40-meter-walk test (40-MWT).RESULTS: The coefficient of variance of cIKS during the IVIg and SCIg treatment periods was unchanged (mean ± SD: 6.97 ± 4.83% vs. 5.50 ± 3.13%, P = 0.21). The variations in the 9-HPT and 40-MWT were significantly lower in the SCIg group (P = 0.01 and P = 0.005, respectively).CONCLUSION: When therapy was changed from IVIg to SCIg, fluctuation of muscle strength was unchanged, but performance fluctuations were diminished. Muscle Nerve, 2017.

AB - INTRODUCTION: Variations in muscle strength and function have not been studied in patients with chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy whose treatment regimen has been changed from intravenous to subcutaneous immunoglobulin (IVIg to SCIg).METHODS: In a prospective, open-label study, patients were changed from monthly IVIg to weekly SCIg. The primary endpoint was variation in isokinetic muscle strength (cIKS). Secondary endpoints were variations in Medical Research Council (MRC) score, grip strength (GS), 9-hole-peg test (9-HPT), and 40-meter-walk test (40-MWT).RESULTS: The coefficient of variance of cIKS during the IVIg and SCIg treatment periods was unchanged (mean ± SD: 6.97 ± 4.83% vs. 5.50 ± 3.13%, P = 0.21). The variations in the 9-HPT and 40-MWT were significantly lower in the SCIg group (P = 0.01 and P = 0.005, respectively).CONCLUSION: When therapy was changed from IVIg to SCIg, fluctuation of muscle strength was unchanged, but performance fluctuations were diminished. Muscle Nerve, 2017.

KW - chronic inflammatory demyelinating polyneuropathy

KW - intravenous immunoglobulin

KW - multifocal motor neuropathy

KW - subcutaneous immunoglobulin

UR - http://www.scopus.com/inward/record.url?scp=85034272437&partnerID=8YFLogxK

U2 - 10.1002/mus.25967

DO - 10.1002/mus.25967

M3 - Journal article

C2 - 28881389

SN - 0148-639X

VL - 57

SP - 610

EP - 614

JO - Muscle & Nerve

JF - Muscle & Nerve

IS - 4

ER -

Comparisons in fluctuation of muscle strength and function in patients with immune-mediated neuropathy treated with intravenous versus subcutaneous immunoglobulin

Abstract

Keywords

Access to Document

AUB Link

Other files and links

Fingerprint

Cite this